PCRX241220C17500
- 2.25
- 0.000.00%
Pacira BioSciences Newsroom
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39
Pacira BioSciences Analyst Ratings
Pacira BioSciences Price Target Cut to $17.00/Share From $25.00 by Barclays
Pacira BioSciences Is Maintained at Equal-Weight by Barclays
Barclays Reaffirms Their Hold Rating on Pacira Pharmaceuticals (PCRX)
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $22
Pacira BioSciences Analyst Ratings
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Sell Rating
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Sell Rating
Pacira BioSciences Analyst Ratings
Jefferies Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Cuts Target Price to $18
Jefferies & Co Adjusts Pacira BioSciences Price Target to $18 From $15, Maintains Buy Rating
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Pacira BioSciences Analyst Ratings
Truist Financial Downgrades Pacira BioSciences(PCRX.US) to Sell Rating, Announces Target Price $8
Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25
Pacira Pharmaceuticals (PCRX) Gets a Hold From Barclays